Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Researchers at the University of Michigan have engineered nanoparticles that cross the blood-brain barrier and make stubborn gliomas vulnerable to radiation. In mouse models, the combo therapy cured 60% of animals — and even trained their immune systems to fight off future tumors. Phase 1 clinical trials are on the horizon.
Brain tumors called mIDH1 gliomas — affecting roughly 7,000 patients and disproportionately striking younger adults — are notoriously hard to treat. They grow slowly, resist radiation, and can recur in an incurable form. The culprit? A mutated enzyme that ramps up the cell's "self-cleaning" autophagy pathway, making tumor cells better at repairing DNA damage caused by radiation.
University of Michigan researchers, publishing in Nature Communications, developed a clever workaround: engineered nanoparticles injected into the bloodstream that cross the blood-brain barrier and deliver small RNAs directly into tumor cells to shut down autophagy. When combined with radiation therapy in mouse models, the approach didn't just shrink tumors — it generated lasting immune memory, allowing mice to eliminate recurrent tumors without any additional treatment.
By the Numbers:
Why it matters: Current autophagy inhibitors can't cross the blood-brain barrier and carry significant side effects. This nanoparticle approach sidesteps both problems, and the immune memory effect could be a game-changer for preventing relapse — one of the biggest challenges in brain cancer care. Phase 1 trials are planned.
